As a teenager, Kat Royston had a lot of questions. Then an advanced-placement class in physics convinced her all the answers were out there.
OAK RIDGE, Tenn., Feb. 19, 2020 — The U.S. Department of Energy’s Oak Ridge National Laboratory and the Tennessee Valley Authority have signed a memorandum of understanding to evaluate a new generation of flexible, cost-effective advanced nuclear reactors.
As scientists study approaches to best sustain a fusion reactor, a team led by Oak Ridge National Laboratory investigated injecting shattered argon pellets into a super-hot plasma, when needed, to protect the reactor’s interior wall from high-energy runaway electrons.
Ask Tyler Gerczak to find a negative in working at the Department of Energy’s Oak Ridge National Laboratory, and his only complaint is the summer weather. It is not as forgiving as the summers in Pulaski, Wisconsin, his hometown.
For the first time, Oak Ridge National Laboratory has completed testing of nuclear fuels using MiniFuel, an irradiation vehicle that allows for rapid experimentation.
The Department of Energy’s Oak Ridge National Laboratory is collaborating with industry on six new projects focused on advancing commercial nuclear energy technologies that offer potential improvements to current nuclear reactors and move new reactor designs closer to deployment.
Scientists from Oak Ridge National Laboratory performed a corrosion test in a neutron radiation field to support the continued development of molten salt reactors.
Thought leaders from across the maritime community came together at Oak Ridge National Laboratory to explore the emerging new energy landscape for the maritime transportation system during the Ninth Annual Maritime Risk Symposium.
Experts focused on the future of nuclear technology will gather at Oak Ridge National Laboratory for the fourth annual Molten Salt Reactor Workshop on October 3–4.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.